Noncognitive symptoms and long-term treatment expectations for Alzheimer disease

Alzheimer Disease and Associated Disorders
Rafael Blesa

Abstract

Alzheimer disease (AD) is characterized by both cognitive and noncognitive symptoms that can lead to functional impairment, increased caregiver burden, and institutionalization. Pharmacologic therapies traditionally used to treat cognitive symptoms of AD may prevent and/or control many noncognitive symptoms as well. The acetylcholinesterase inhibitors (AChEIs) galantamine, rivastigmine, and donepezil have been shown to maintain or improve function for at least 1 year. They also have been shown to improve or delay the onset of neuropsychiatric and behavioral symptoms. These noncognitive benefits can impact greatly the lives of patients with AD as well as the persons who care for them.

References

Nov 1, 1984·The American Journal of Psychiatry·W G RosenK L Davis
Jan 1, 1996·Neurology·M S MegaJ Gornbein
Nov 26, 1997·Neurology·W M Clark
Jan 1, 1997·Alzheimer Disease and Associated Disorders·S H Ferris, A Kluger
Jul 1, 1998·International Journal of Geriatric Psychiatry·C DonaldsonA Burns
Jan 7, 1999·Alzheimer Disease and Associated Disorders·N NagaratnamL Palazzi
Sep 29, 1999·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·I GélinasS Gauthier
May 10, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·J L CummingsR L Brooks
Sep 6, 2000·Dementia and Geriatric Cognitive Disorders·B WinbladO Almkvist
Sep 6, 2000·Dementia and Geriatric Cognitive Disorders·R Blesa
Aug 29, 2001·Neurology·H FeldmanUNKNOWN Donepezil MSAD Study Investigators Group
Oct 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·K RockwoodD Wilkinson
Dec 18, 2001·International Journal of Geriatric Psychiatry·C G LyketsosJ C Breitner
Aug 22, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Steven G PotkiGeorge Grossberg
Jul 16, 2003·Clinical Therapeutics·Timo ErkinjunttiUNKNOWN GAL-INT-6 Study Group

❮ Previous
Next ❯

Citations

Apr 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yukiko YoshidaTsunehiko Ikeda
May 2, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Fadi Massoud
Oct 26, 2006·American Journal of Alzheimer's Disease and Other Dementias·Carol F Lippa
Aug 27, 2011·Journal of Clinical Psychopharmacology·Mark J RapoportMichel Bédard
Nov 8, 2005·CNS Spectrums·Jeffrey L Cummings

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.